Company Description
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies.
The company’s product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC.
It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC.
The company was founded in 2016 is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Eli Wallace |
Contact Details
Address: 256 E. Grand Avenue, Suite 104 South San Francisco, California 94080 United States | |
| Phone | 650 405 4770 |
| Website | bbotx.com |
Stock Details
| Ticker Symbol | BBOT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001869105 |
| ISIN Number | US1079241022 |
Key Executives
| Name | Position |
|---|---|
| Eli M. Wallace Ph.D. | Chief Executive Officer and Director |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Scientific Officer |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical and Development Officer |
| Uneek Mehra M.B.A. | Chief Financial Officer |
| Howard Y. Chang M.D., Ph.D. | Vice President of Operations |
| Aaron Chan J.D. | Vice President of Legal |
| Angela Peters | Senior Vice President of People |
| Idan Elmelech M.A., M.B.A. | Senior Vice President of Strategy and Business Development |
| Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Keshi Wang Ph.D. | Senior Vice President of DMPK and Clinical Pharmacology |